Home · Open Lab · Lot RGX-26-RGNX-744
RGX-26-RGNX-744Superseded
GHK-CU · 100 MG · Dermal Research · COA NS-2026-05187

Release test results

99.669%HPLC purity · meets ≥ 99.5% spec
Mass-spec identityConfirmed · 100.6 mg
Related impurities (total)0.331%
Endotoxin<1.0 EU/mg
HPLC retention time7.33 min
MethodHPLC + LC-MS
ResultPass · meets spec
Verify COA at Nordicstar Labs → All certificates

Lot record

CompoundGHK-CU
Presentation100 MG
Lot numberRGX-26-RGNX-744
COA numberNS-2026-05187
Test date02 Sep 2026
Release date05 Sep 2026
Independent labNordicstar Labs
StatusSuperseded

GHK-CU — lot history

LotPresentationTestedHPLC purityStatus
RGX-26-RGNX-105550 MGSep 8, 202699.606%Current
RGX-26-RGNX-1056100 MGSep 6, 202699.568%Current
RGX-26-RGNX-74550 MGSep 6, 202699.745%Superseded
RGX-26-RGNX-644100 MGSep 5, 202699.769%Superseded
RGX-26-RGNX-64550 MGSep 4, 202699.707%Superseded
RGX-26-RGNX-744 this lot100 MGSep 2, 202699.669%Superseded
!
Research use only

This lot record documents a research compound sold for laboratory use only — not for human or animal consumption. Results are as tested by Nordicstar Labs; retained samples are archived for five years. Research Use Agreement →